Sarhan Wessam A, Azzazy Hassan M E
Novel Diagnostics and Therapeutics Research Group, YJ-Science and Technology Research Centre, School of Sciences and Engineering, The American University in Cairo, AUC Avenue, SSE 1184, P.O. Box 74, New Cairo, 11835, Egypt .
Expert Rev Anti Infect Ther. 2015 Jan;13(1):91-101. doi: 10.1586/14787210.2015.990383.
Bacterial resistance is not only restricted to human infections but is also a major problem in food. With the marked decrease in produced antimicrobials, the world is now reassessing bacteriophages. In 2006, ListShield™ received the US FDA approval for using phage in food. Nevertheless, regulatory approval of phage-based therapeutics is still facing many challenges. This review highlights the use of bacteriophages as biocontrol agents in the food industry. It also focuses on the challenges still facing the regulatory approval of phage-based therapeutics and the proposed approaches to overcome such challenges.
细菌耐药性不仅局限于人类感染，在食品领域也是一个重大问题。随着抗菌剂产量的显著下降，全球正在重新评估噬菌体。2006年，ListShield™获得美国食品药品监督管理局（FDA）批准可在食品中使用噬菌体。然而，基于噬菌体的疗法的监管批准仍面临诸多挑战。本综述重点介绍了噬菌体在食品工业中作为生物防治剂的应用。它还关注基于噬菌体的疗法在监管批准方面仍面临的挑战以及为克服这些挑战而提出的方法。
